Home / Lifestyle / Health & Fitness / Article /
WHO releases guideline on GLP-1 therapies for obesity; here’s what you need to know
Updated On: 03 December, 2025 06:06 PM IST | Mumbai | mid-day online correspondent
WHO outlines first-ever global recommendations for GLP-1 medicines in obesity care, stressing long-term use and behavioural support
Image for representational purpose only. Photo Courtesy: File pic
The World Health Organization has released its first global guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity, recognising the condition as a chronic and relapsing disease. The move comes amid rising global demand for GLP-1 medications—such as semaglutide and liraglutide—currently used for diabetes and weight management. Here’s what the new guidance means and why it matters.
What are GLP-1 therapies?
How do you like the new new mid-day.com experience? Share your feedback and help us improve.
Trending Stories
Latest Photos
Latest Videos
Latest Web Stories
ADVERTISEMENT
Mid-Day Fast
ADVERTISEMENT
ADVERTISEMENT